Rockwell Medical (NASDAQ:RMTI) Now Covered by StockNews.com

StockNews.com assumed coverage on shares of Rockwell Medical (NASDAQ:RMTI – Get Rating) in a report issued on Thursday. The firm set a “hold” rating on the stock.

Several other analysts also recently weighed in on RMTI. HC Wainwright decreased their price objective on Rockwell Medical from $5.00 to $3.00 and set a “buy” rating for the company in a report on Tuesday, January 18th. Zacks Investment Research upgraded Rockwell Medical from a “sell” rating to a “hold” rating in a report on Thursday, March 17th.

RMTI stock opened at $0.34 on Thursday. The company has a debt-to-equity ratio of 5.21, a current ratio of 1.68 and a quick ratio of 1.49. The business has a 50-day moving average price of $0.37 and a 200 day moving average price of $0.41. The company has a market capitalization of $32.33 million, a P/E ratio of -1.01 and a beta of 1.09. Rockwell Medical has a 1-year low of $0.30 and a 1-year high of $1.06.

Institutional investors and hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new position in Rockwell Medical in the third quarter valued at about $25,000. Renaissance Technologies LLC grew its stake in Rockwell Medical by 81.1% in the fourth quarter. Renaissance Technologies LLC now owns 225,534 shares of the company’s stock valued at $92,000 after purchasing an additional 101,000 shares during the last quarter. Metropolitan Life Insurance Co NY purchased a new position in Rockwell Medical in the first quarter valued at about $106,000. Verdence Capital Advisors LLC grew its stake in Rockwell Medical by 25.1% in the fourth quarter. Verdence Capital Advisors LLC now owns 443,545 shares of the company’s stock valued at $182,000 after purchasing an additional 88,980 shares during the last quarter. Finally, Perkins Capital Management Inc. grew its stake in Rockwell Medical by 34.5% in the fourth quarter. Perkins Capital Management Inc. now owns 2,957,025 shares of the company’s stock valued at $1,212,000 after purchasing an additional 758,400 shares during the last quarter. Institutional investors own 27.88% of the company’s stock.

Rockwell Medical Company Profile (Get Rating)

Rockwell Medical, Inc operates as a biopharmaceutical company that targets end-stage renal disease and chronic kidney disease with therapies and products for the treatment of iron deficiency and hemodialysis in the United States and internationally. The company offers Triferic Dialysate and Triferic AVNU, an iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.

Featured Stories